我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
100.0%
暂无批准数据
- Quanterix Corporation has completed its acquisition of Akoya Biosciences, establishing a scaled leader in early disease detection for neurology, oncology, and immunology markets. - The transaction expands Quanterix's served addressable market from $1 billion to $5 billion by creating the first integrated platform capable of measuring biomarkers across blood and tissue. - Under the merger terms, Quanterix issued approximately 7.8 million shares and paid $20 million in cash, with the combined company maintaining $163 million in cash post-transaction. - The acquisition is expected to accelerate the path to profitability by 2026 through significant scale advantages and comprehensive protein biomarker solutions.
